Nonviral genome editing using CRISPR nanocomplexes
Date Posted: 16/10/2018
The spread of multidrug-resistant bacteria represents a major public health threat and challenge for the pharmaceutical industry. Gene therapeutics, which involves the administration of drugs designed to either induce or suppress the expression of disease genes, represents a promising new avenue for the development of narrow-spectrum antimicrobial agents. However, owing to the difficulties in drug penetration through the thick bacterial cell wall, successful delivery of nonviral targeted gene therapies remains challenging. For more information, please click here.